ISTH Congress Abstracts

Official abstracts site for the ISTH Congress

MENU 
  • Home
  • Congress Archive
    • ISTH 2022 Congress
    • ISTH 2021 Congress
    • ISTH 2020 Congress
  • Resources
  • Search

ISTH 2020 Congress

Coagulation and Natural Anticoagulants » Coagulation Factors and Inhibitors

Theme Navigation

  • ISTH 2020 Congress
    • Coagulation and Natural Anticoagulants
      • Coagulation Factors and Inhibitors

Abstract Number: PB0201

A Comparison of Mass and Potency Equated Bovine and Porcine Heparins

S. Krishnappan, F. Siddiqui, A. Farooqui, O. Iqbal, A. Kouta, D. Hoppensteadt, W. Jeske, J. Walenga, J. Fareed

Abstract Number: PB0189

A Double Heterozygous Factor VII (FVII) Deficiency: Exon 9 Missense Mutation (Arg364Gln – FVII Padua) and a Novel Exon 3 Missense Mutation (Ala87Gly)

C. Gallardo1, C.L.L. Sum1, L.J.L. Wong1, K.H. Ong1, L.L. Goh2

Abstract Number: PB0223

A Novel Coagulation Factor VIII with Reduced Immunogenicity

K. Winterling1, W. Martin2, A.S. De Groot2, J. Daufenbach1, J. Schüttrumpf3, S. Kistner1

Abstract Number: PB0169

A Novel Prediction Platform to Enhance the Design of Therapeutic SERPINs

W. Sanrattana1, S. Smits1, D. Monroe2, C. Maas1, S. de Maat1

Abstract Number: PB0158

A Novel Rare C. – 39C>T Mutation in the PROS1 5’UTR Causes Protein S Deficiency by Creating a New Upstream Translation Initiation Codon and an Overlapping Open Reading frame

B. Jaspard-Vinassa1, C. Proust2,3, O. Soukarieh2,3, C. Mouton4, Y. Huguelin4, M. Roux5, J. Constans6, A. Boland7, R. Olaso7, J.-F. Deleuze7, P.-E. Morange8, S. Labrouche-Colomer1,4, D.-A. Trégouët2,3, GENMED Consortium

Abstract Number: PB0224

A Sensitive and Specific Assay to Measure TF Activity in Cell-derived Extracellular Vesicles Based on Thrombin Generation

B. Østerud, N. Latysheva, O. Snir, J.-B. Hansen

Abstract Number: PB0162

Acquired Haemophilia Spanish Registry, First Five Years of Activity

M.E. Mingot-Castellano1,2, J.M. Bastida-Bermejo3, S. Haya4, J. Pardos-Gea5, M.D.C. Fernandez-Sanchez de Mora6, R. Lluch7, R. Nuñez8, M.T. Alvarez-Roman9, I. Soto-Ortega10, J.M. Martín-Antoran11, J.A. Rodriguez-Garcia12, M. Carrasco-Exposito13, J.A. Rodriguez-Alen14, C. Cervero-Santiago15, M. Perez-Sanchez16, R. Rodriguez-Gonzalez17, N. Fernandez-Mosteirin18, M.N. Alonso-Escobar19, A. Moreto-Quintana20, P. Marco-Vera21, Registro Español de Hemofilia Adquirida

Abstract Number: PB0154

Activated recombinant Factor VII (rFVIIa) Inhibitor in Iran: Immunogenicity is a Major Challenge through Treated Bleeds Covered with rFVIIa

P. Eshghi1, M. Ahmadinejad2, M. Karimi3

Abstract Number: PB0227

Addition of Histone Deacetylase Inhibitors Increases Recombinant Factor V Expression in BHK Cells

T. Petrillo1, J.C. Small1, R.M. Camire1,2

Abstract Number: PB0239

Always Ask Relevant Questions to Patients Might Be They Tell You the Diagnosis

A. Naz1, T. Masood2, N. Saqlain3, N. Samad4, T. Shamsi5

Abstract Number: PB0226

Anti-factor V Inhibitor after Liver Transplantation

A. Ciavarella1, A. Artoni1, M. Capecchi1, S. Bhoori2, V. Mazzaferro2, C. Novembrino1, A. Cairo1, M. Clerici1, C. Valsecchi3, F. Peyvandi1, I. Martinelli1

Abstract Number: PB0213

Anticoagulant Effect of Novel Nanoparticles Functionalized with Synthetic Piperazinone Derivatives as FXa Inhibitors

J. Salazar1,2, C. Rojas2, F. Santana-Romo2, A. Romero Bohorquez3, C. Vilos4, F. Zacconi2,5

Abstract Number: PB0182

Anticoagulant Effects of Parenteral Sulodexide as Measured by Activated Clotting Time. Relevance to Dosing in Various Indications

B. Daravath1, J. Fareed1, O. Iqbal1, A. Kouta1, D. Hoppensteadt1, W. Jeske1, F. Siddiqui1, M. Lewis1, B. Lewis2

Abstract Number: PB0166

Anticoagulation with the Novel, Small-molecule Factor XIa (fXIa) Antagonist, EP-7041, Prevents Oxygenator Clotting but Conserves Hemostasis in a Canine Extracorporeal Circulation (ECMO) Model

M.A. Kurz1, C.V. Pollack, Jr.1, J.M. Connors2, J.H. Levy3, C. Drummond4, D. Klein5, H.D. Josuns5, R. Pielemeier4, J. Buchino4, P. Osborne4, N.J. Hayward1

Abstract Number: PB0179

Antithrombotic Effects of a Novel Small Molecular Fxia Inhibitor BMS-986177/JNJ-70033093 in a Rabbit AV-Shunt Model of Thrombosis

X. Wang, Q. Li, F. Du, N. Shukla, A. Nawrocki, M. Chintala

Abstract Number: PB0219

Are the Plasma Levels Thresholds of DOAC Rationale and Appropriate for Clinical Decision-making? A Reappraisal Using Thrombin Generation Testing

J. Evrard1, J.-M. Dogné1,2, M. Hardy3,4, S. Lessire3, V. Maloteau1, L. Morimont1,5, F. Mullier4, R. Siriez1, J. Douxfils1,5

Abstract Number: PB0236

Assessment of Four Factor Prothrombin Complex Concentrate (4F-PCC) Usage in Emergency Department Patients: A Single Center Experience

H. McRae, F. Kara, R. Baum, N. Acquisto, M. Refaai

Abstract Number: PB0234

Baseline VWF Antigen Level Is Associated with the Outcome of Immune Tolerance Induction Using pdFVIII/VWF Concentrate in Hemophilia A with Inhibitor

Z. Li1, Z. Chen1, X. Cheng1, X. Wu1, G. Li1, Y. Zhen1, S. Cai2, M.-C. Poon3, R. Wu1

Abstract Number: PB0214

Bisecting the Role of the C-terminal End of Antithrombin: Natural Variants due to a Frameshift at Different Secondary Structures May Exacerbate or Ameliorate a New Dominant-negative Effect

C. Bravo-Perez1, M. Toderici1, B. de la Morena-Barrio1, J. Padilla1, A. Miñano1, A. Palomo2, H. Perez-Sanchez3, J. Martinez-Menarguez4, J. Chambers5, S. Marciniak5, V. Vicente1, J. Corral1, M.E. de la Morena-Barrio1

Abstract Number: PB0206

Characterisation and Evaluation of a Candidate Bethesda Assay Reference Reagent Developed from Recombinant, Patient-Derived FVIII Inhibitors

C. Coxon1, J. Beavis2, X. Yu3, S. Diamond3, A. Riches1, S. Raut1

  • 1
  • 2
  • 3
  • …
  • 5
  • Next Page »

« View all themes from the ISTH 2020 Congress

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2023 John Wiley & Sons, Inc. All Rights Reserved.
Wiley